Federal regulators Friday approved the use of the antiviral drug remdesivir for covid-19 outpatients at high risk of being hospitalized, providing a new treatment option for doctors struggling with shortages of effective drugs to counter _...Read More_

"A total of 562 patients took part in the study over an eight month period.The double-blind, randomized, placebo-controlled trial was meant to evaluate the efficacy and safety of a three-day course of remdesivir in high-risk, _...Read More_